Risk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis

Abstract

Background Prophylactic endoscopic variceal band ligation (EVL) is frequently performed in patients with liver cirrhosis. The aim of our study was to identify factors associated with early upper gastrointestinal bleeding (UGIB) in cirrhosis patients after prophylactic EVL.

Methods 787 nonemergency EVLs performed in 444 patients in two German University medical centers were analyzed retrospectively.

Results Within 30 days after EVL, 38 UGIBs were observed (4.8 % of all procedures). Bilirubin levels (hazard ratio [HR] 1.5, 95 % confidence interval [CI] 1.2–2.0 for a 2-fold increase) and presence of varices grade III/IV according to Paquet (HR 2.6, 95 %CI 1.3–5.0 compared with absence or smaller sized varices) were independently associated with UGIB following EVL. International normalized ratio (INR) was associated with bleeding events in the univariate analysis but did not reach statistical significance after adjustment for bilirubin and presence of varices grade III/IV (HR 1.2, 95 %CI 0.9–1.6 for an increase by 0.25). There was no statistically significant association between platelet count or fibrinogen levels and UGIB. Substitution of coagulation products did not affect incidence of bleeding after EVL, which also applied to patients with “coagulopathy” (INR > 1.5 and/or platelet count < 50 × 10⁹/L). No association between proton pump inhibitor therapy and post-EVL UGIB was observed.

Conclusions EVL is a safe procedure and immediate bleeding complications are rare. Serum bilirubin levels and size of varices, rather than coagulation indices, are associated with UGIB after EVL. Our data do not support the preventive substitution of blood or coagulation products.

^* These authors contributed equally to this work.

Publication History

Received: 04 September 2019

Accepted: 02 June 2020

Article published online:
07 September 2020

• References

• 1 Simonetto DA, Shah VH, Kamath PS. Primary prophylaxis of variceal bleeding. Clin Liver Dis 2014; 18: 335-345
• 2 Sharma M, Singh S, Desai V. et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis. Hepatology 2019; 69: 1657-1675
• 3 Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: the modern management of portal hypertension - primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther 2008; 28: 178-186
• 4 D’Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997; 11: 243-256
• 5 de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63: 743-752
• 6 de Franchis R, Pascal JP, Ancona E. et al. Definitions, methodology and therapeutic strategies in portal hypertension. A consensus development workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol 1992; 15: 256-261
• 7 Laine L, el-Newihi HM, Migikovsky B. et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 1993; 119: 1-7
• 8 Baroncini D, Milandri GL, Borioni D. et al. A prospective randomized trial of sclerotherapy versus ligation in the elective treatment of bleeding esophageal varices. Endoscopy 1997; 29: 235-240
• 9 Sarin SK, Govil A, Jain AK. et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997; 26: 826-832
• 10 Stiegmann GV, Goff JS, Michaletz-Onody PA. et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992; 326: 1527-1532
• 11 Shaheen NJ, Stuart E, Schmitz SM. et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology 2005; 41: 588-594
• 12 Caldwell SH, Hoffman M, Lisman T. et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-1046
• 13 Afdhal N, McHutchison J, Brown R. et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008; 48: 1000-1007
• 14 Drolz A, Horvatits T, Roedl K. et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis. Hepatology 2016; 64: 556-568
• 15 Lisman T, Caldwell SH, Burroughs AK. et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010; 53: 362-371
• 16 Kamath PS, Wiesner RH, Malinchoc M. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
• 17 Paquet KJ. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices – a prospective controlled randomized trial. Endoscopy 1982; 14: 4-5
• 18 Sey MSL, Mohammed SB, Brahmania M. et al. Comparative outcomes in patients with ulcer- vs non-ulcer-related acute upper gastrointestinal bleeding in the United Kingdom: a nationwide cohort of 4474 patients. Aliment Pharmacol Ther 2019; 49: 537-545
• 19 Ripatti S, Palmgren J. Estimation of multivariate frailty models using penalized partial likelihood. Biometrics 2000; 56: 1016-1022
• 20 Austin PC, Wagner P, Merlo J. The median hazard ratio: a useful measure of variance and general contextual effects in multilevel survival analysis. Stat Med 2017; 36: 928-938
• 21 Tripodi A. Tests of coagulation in liver disease. Clin Liver Dis 2009; 13: 55-61
• 22 Napolitano G, Iacobellis A, Merla A. et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med 2017; 38: 79-82
• 23 De Gottardi A, Thevenot T, Spahr L. et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol 2009; 7: 906-909
• 24 Vieira da Rocha EC, D’Amico EA, Caldwell SH. et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. Clin Gastroenterol Hepatol 2009; 7: 988-993
• 25 Garcia-Tsao G, Abraldes JG, Berzigotti A. et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65: 310-335
• 26 Tripathi D, Stanley AJ, Hayes PC. et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015; 64: 1680-1704
• 27 Götz M, Anders M, Biecker E. et al. [S2k Guideline Gastrointestinal Bleeding – Guideline of the German Society of Gastroenterology DGVS]. Z Gastroenterol 2017; 55: 883-936
• 28 Stanworth SJ, Grant-Casey J, Lowe D. et al. The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion 2011; 51: 62-70
• 29 Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006; 46: 1279-1285
• 30 Afdhal NH, Giannini EG, Tayyab G. et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367: 716-724
• 31 Giannini EG, Stravitz RT, Caldwell SH. Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. Hepatology 2014; 60: 1442
• 32 Bedreli S, Sowa JP, Malek S. et al. Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with cirrhosis. Liver Int 2017; 37: 562-568
• 33 Tripodi A, Primignani M, Chantarangkul V. et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124: 132-136
• 34 De Pietri L, Bianchini M, Montalti R. et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. Hepatology 2016; 63: 566-573
• 35 Saner FH, Bezinover D, Sakai T. Assessment of haemostasis in patients with liver cirrhosis. Eur J Anaesthesiol 2017; 34: 33-34
• 36 Wadhawan M, Dubey S, Sharma BC. et al. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child’s status. Dig Dis Sci 2006; 51: 2264-2269
• 37 Garcia-Tsao G, Groszmann RJ, Fisher RL. et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5: 419-424
• 38 Berzigotti A, Seijo S, Arena U. et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013; 144: 102-111. e101
• 39 Li J, Han B, Li H. et al. Association of coagulopathy with the risk of bleeding after invasive procedures in liver cirrhosis. Saudi J Gastroenterol 2018; 24: 220-227
• 40 Kang SH, Yim HJ, Kim SY. et al. Proton pump inhibitor therapy is associated with reduction of early bleeding risk after prophylactic endoscopic variceal band ligation: a retrospective cohort study. Medicine (Baltimore) 2016; 95: e2903
• 41 Zhu J, Qi X, Yu H. et al. Acid suppression in patients treated with endoscopic therapy for the management of gastroesophageal varices: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2018; 12: 617-624
• 42 Dultz G, Piiper A, Zeuzem S. et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther 2015; 41: 459-466
• 43 Li Y, Guo X, Bai Z. et al. Banana may be forbidden after endoscopic variceal ligation: a case report. Transl Gastroenterol Hepatol 2019; 4: 13